DO34

Overview

DO34 is a selective DAGL inhibitor, with an IC 50 of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 blocks de novo 2-AG synthesis, and suppresses tonic CB 1 receptor activation. DO34 blocks depolarization-induced suppression of excitation and inhibition in the cerebellum and hippocampus. DO34 regulates feeding behavior and locomotor activity in mice. DO34 abolishes AM251-mediated enhancement of parallel fiber-evoked excitatory postsynaptic currents in cerebellar slices from MAGL global knockout mice. DO34 can be used for the research of energy balance disorder and neuroinflammation.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > DAGL

Product Information

• Catalog No.: HY-117771
• CAS No.: 1848233-58-8
• Molecular Formula: C26H28F3N5O4
• Molecular Weight: 531.53
• Purity: 99.30%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 10 mg/mL (18.81 mM); Clear solution
• Availability: In-stock

Source

Original product source